{'fraction_non_alphanumeric': 0.03305785123966942, 'fraction_numerical': 0.014462809917355372, 'mean_word_length': 5.2094017094017095, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Metabolic tumour volume and response to therapy in diffuse large B‐cell lymphoma

GC St I/II (10 pts) No‐GC St I/II (10pts) Diffuse large B‐cell lymphoma (DLBCL) is the most common type of aggressive lymphoma, but it represents a heterogeneous entity, both clinically and morphologically. Despite the use of anthracycline‐based chemotherapy associated with anti‐CD20 monoclonal antibody (eg, rituximab), durable remission is achieved in only 40% to 50% of patients. The prognosis of DLBCLs is estimated using clinical parameters, combined in scores such as the international prognostic index (IPI), and based on histological differences, as in germinal centre (GC) DLBCLs or activated lymphocytes DLBCLs. FDG‐PET is recommended as one of the best imaging tool for staging and response assessment in DLBCL. The total metabolic tumour volume (MTV) is the volumetric sum of FDG positive regions of DLBCL. MTV at diagnosis could be used as a prognostic biomarker in DLBCL. Here, we present retrospectively 51 consecutive patients affected by DLBCL treated in our department between January 2013 and December 2017 and studied with FDG‐PET at the diagnosis and at the end of treatment. Patients' clinical features are reported in Table 1. We studied the possible correlations between MTV at the diagnosis and the rate of complete remission (CR) after first‐line standard therapy and the relationships between MTV and IPI score, stage, and tumour cell origin.